Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MRVINASDAQ:STOKNASDAQ:TARANASDAQ:VERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRVIMaravai LifeSciences$2.02-2.4%$2.33$1.67▼$11.56$513.76M0.182.36 million shs1.19 million shsSTOKStoke Therapeutics$9.76+2.6%$7.84$5.35▼$17.58$532.87M1.09711,971 shs571,597 shsTARAProtara Therapeutics$3.50+2.9%$4.01$1.60▼$10.48$128.69M1.6783,079 shs557,843 shsVERVVerve Therapeutics$5.67+3.8%$5.22$2.86▼$9.31$503.47M1.861.78 million shs2.06 million shs20 Stocks to Sell NowGet This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRVIMaravai LifeSciences+2.99%+7.25%-12.29%-58.85%-73.63%STOKStoke Therapeutics+0.42%+3.15%+31.90%-9.51%-19.81%TARAProtara Therapeutics-3.41%-13.71%-25.76%-24.78%+9.68%VERVVerve Therapeutics-4.71%+4.00%+4.60%-29.09%-12.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMRVIMaravai LifeSciences4.1459 of 5 stars4.11.00.04.41.71.71.3STOKStoke Therapeutics3.4907 of 5 stars3.60.00.04.82.81.70.0TARAProtara Therapeutics2.2136 of 5 stars3.52.00.00.02.31.70.6VERVVerve Therapeutics3.6935 of 5 stars4.52.00.00.03.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMRVIMaravai LifeSciences 2.18Hold$6.34214.05% UpsideSTOKStoke Therapeutics 3.13Buy$24.67152.73% UpsideTARAProtara Therapeutics 3.00Buy$20.40482.86% UpsideVERVVerve Therapeutics 3.00Buy$25.75354.14% UpsideCurrent Analyst Ratings BreakdownLatest TARA, STOK, MRVI, and VERV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025TARAProtara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/16/2025TARAProtara TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$12.004/15/2025VERVVerve TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $24.004/15/2025VERVVerve TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight4/15/2025VERVVerve TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$32.00 ➝ $39.004/14/2025VERVVerve TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $25.004/9/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/25/2025MRVIMaravai LifeSciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$7.00 ➝ $5.003/25/2025VERVVerve TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/25/2025VERVVerve TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/21/2025MRVIMaravai LifeSciencesStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMRVIMaravai LifeSciences$259.19M1.98$0.05 per share41.71$3.14 per share0.64STOKStoke Therapeutics$36.56M14.58N/AN/A$3.57 per share2.73TARAProtara TherapeuticsN/AN/AN/AN/A$6.01 per shareN/AVERVVerve Therapeutics$32.33M15.57N/AN/A$7.31 per share0.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMRVIMaravai LifeSciences-$119.03M-$1.02N/AN/AN/A-81.13%-6.61%-3.45%5/6/2025 (Estimated)STOKStoke Therapeutics-$104.70M-$1.68N/AN/AN/A-629.90%-54.45%-40.77%5/5/2025 (Estimated)TARAProtara Therapeutics-$40.42M-$2.40N/AN/AN/AN/A-55.96%-49.06%5/1/2025 (Estimated)VERVVerve Therapeutics-$200.07M-$2.35N/AN/AN/A-807.65%-35.23%-27.65%5/14/2025 (Estimated)Latest TARA, STOK, MRVI, and VERV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MRVIMaravai LifeSciences-$0.07N/AN/AN/A$44.01 millionN/A5/14/2025Q1 2025VERVVerve Therapeutics-$0.71N/AN/AN/AN/AN/A5/5/2025Q1 2025STOKStoke Therapeutics-$0.42N/AN/AN/A$27.37 millionN/A5/1/2025Q1 2025TARAProtara Therapeutics-$0.47N/AN/AN/AN/AN/A3/24/2025Q4 2024STOKStoke Therapeutics-$0.56-$0.18+$0.38-$0.18$4.20 million$22.61 million3/12/2025Q4 2024TARAProtara Therapeutics-$0.57-$0.48+$0.09-$0.48N/AN/A2/27/2025Q4 2024VERVVerve Therapeutics-$0.72-$0.58+$0.14-$0.58$3.94 million$13.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMRVIMaravai LifeSciencesN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMRVIMaravai LifeSciences0.8910.749.94STOKStoke TherapeuticsN/A5.095.09TARAProtara TherapeuticsN/A9.859.85VERVVerve TherapeuticsN/A13.0513.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMRVIMaravai LifeSciences50.25%STOKStoke TherapeuticsN/ATARAProtara Therapeutics38.13%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipMRVIMaravai LifeSciences0.63%STOKStoke Therapeutics11.30%TARAProtara Therapeutics12.50%VERVVerve Therapeutics19.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMRVIMaravai LifeSciences610254.34 million250.94 millionOptionableSTOKStoke Therapeutics10054.60 million46.98 millionOptionableTARAProtara Therapeutics3036.77 million18.05 millionOptionableVERVVerve Therapeutics11088.80 million68.32 millionOptionableTARA, STOK, MRVI, and VERV HeadlinesRecent News About These CompaniesVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Sold by T. Rowe Price Investment Management Inc.April 30 at 5:19 AM | marketbeat.com1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall StreetApril 29 at 7:53 AM | fool.comOne-Time Gene Editing Therapy Shows Big Promise for CholesterolApril 29 at 5:44 AM | medindia.netSyon Capital LLC Takes $302,000 Position in Verve Therapeutics, Inc. (NASDAQ:VERV)April 28 at 5:36 AM | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Sold by Renaissance Technologies LLCApril 28 at 3:41 AM | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Position Reduced by JPMorgan Chase & Co.April 26, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Given Average Recommendation of "Buy" by AnalystsApril 21, 2025 | marketbeat.comWhy Verve Therapeutics Zoomed 40% Higher This WeekApril 18, 2025 | fool.comVerve Therapeutics Sees Unusually Large Options Volume (NASDAQ:VERV)April 17, 2025 | marketbeat.comGuggenheim Raises Verve Therapeutics (NASDAQ:VERV) Price Target to $24.00April 17, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Upgraded to Overweight at Cantor FitzgeraldApril 17, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Expected to Rise, Canaccord Genuity Group Analyst SaysApril 17, 2025 | marketbeat.comBiotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More NewsApril 17, 2025 | finance.yahoo.comVerve’s One-Time Gene Editor Cuts LDL by Nearly 70% in Early TrialApril 17, 2025 | managedhealthcareexecutive.comHC Wainwright Forecasts Strong Price Appreciation for Verve Therapeutics (NASDAQ:VERV) StockApril 16, 2025 | marketbeat.comJ.P. Morgan Sticks to Their Hold Rating for Verve Therapeutics (VERV)April 16, 2025 | markets.businessinsider.comOne-off gene-editing therapy could permanently lower cholesterolApril 16, 2025 | newscientist.comVerve extends gains as Cantor Fitzgerald upgrades on data for cholesterol drugApril 15, 2025 | msn.comVerve Therapeutics price target raised to $24 from $18 at GuggenheimApril 15, 2025 | markets.businessinsider.comCantor upgrades Verve Therapeutics to Overweight after positive dataApril 15, 2025 | markets.businessinsider.comVERV Stock Soars on Superior Efficacy in Phase I Cholesterol StudyApril 15, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeat3 Momentum Stocks That Could Soar Post-Market VolatilityBy Nathan Reiff | April 21, 2025View 3 Momentum Stocks That Could Soar Post-Market VolatilityTARA, STOK, MRVI, and VERV Company DescriptionsMaravai LifeSciences NASDAQ:MRVI$2.02 -0.05 (-2.42%) As of 04:00 PM EasternMaravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.Stoke Therapeutics NASDAQ:STOK$9.76 +0.25 (+2.63%) As of 04:00 PM EasternStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Protara Therapeutics NASDAQ:TARA$3.50 +0.10 (+2.94%) As of 04:00 PM EasternProtara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.Verve Therapeutics NASDAQ:VERV$5.67 +0.21 (+3.85%) As of 04:00 PM EasternVerve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
